BioLoomics
BioLoomics is a Boulder, Colorado preclinical biotechnology company that uses a directed evolution platform in human cells to develop enhanced antibody-drug conjugates (Super-ADCs) for cancer therapeutics, monetizing through co-development partnerships and licensing with large pharmaceutical companies.
- Company typePrivate
- Founded2019
- HeadquartersBoulder, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
BioLoomics firmographics
Firmographics- Name
- BioLoomics
- Legal name
- BioLoomics, Inc.
- Website
- https://bioloomics.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioLoomics is a Boulder, Colorado preclinical biotechnology company that uses a directed evolution platform in human cells to develop enhanced antibody-drug conjugates (Super-ADCs) for cancer therapeutics, monetizing through co-development partnerships and licensing with large pharmaceutical companies.
- Ownership category
- akta.pro rank
BioLoomics industry classification
Industry- Product category
- Biotechnology / Antibody Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where BioLoomics is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioLoomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Co-development Partnerships: BioLoomics plans to form strategic partnerships with large pharmaceutical companies for co-development of Super-ADC therapeutics. Revenue would come from development milestone payments, licensing fees, and potential royalty arrangements.
- Pre-clinical Asset Development: Developing pre-clinical assets internally with intent to out-license or partner with pharmaceutical companies for clinical development and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
BioLoomics product offering
Product offeringCore offering
BioLoomics develops next-generation antibody-drug conjugates (Super-ADCs) using a proprietary directed evolution platform that engineers antibodies in human cells. The Super-ADCs incorporate oligomerizing membrane binding peptides that enhance tumor cell uptake and payload delivery, addressing the limitation of traditional ADCs that deliver less than 1% of chemotherapy payload to tumors. The company develops pre-clinical assets internally and intends to out-license or co-develop them with large pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Brands
- Super-ADCs: A proprietary technology platform that enhances antibody-drug conjugates (ADCs) using oligomerizing membrane binding peptides to improve tumor cell uptake and reduce off-target toxicities.
Products and services
- Super-ADCs (Super Antibody-Drug Conjugates) Next-generation antibody-drug conjugates that incorporate an oligomerizing membrane binding peptide to improve tumor cell uptake. Super-ADCs address the limitation of traditional ADCs that deliver less than 1% of chemotherapy payload to tumors, enhancing payload delivery and reducing off-target toxicities for cancer therapeutics. Targeted at large pharmaceutical companies for co-development partnerships.
- Directed Evolution Platform A proprietary platform for directed evolution of target degrading antibodies using human cells, enabling the design of antibodies with enhanced functionalities for improved cancer therapeutics. The platform is the technological foundation underlying the company's Super-ADC program and pre-clinical pipeline.
- Pre-clinical ADC Asset Development Internal development of pre-clinical antibody-drug conjugate assets for cancer therapeutics using BioLoomics' proprietary directed evolution platform. Assets are developed with the intent to out-license or co-develop with pharmaceutical partners for clinical development and commercialization.
Quantifiable outcome
- Traditional ADCs deliver less than 1% of chemotherapy payload to tumors; Super-ADCs have potential to significantly improve this ratio by enhancing payload delivery through membrane binding peptides
Companies that use BioLoomics
Customer profileSegments1 record
Ideal customer profiles1 record
BioLoomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BioLoomics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Large Pharmaceutical CompaniescoreBioLoomics plans to form strategic partnerships with large pharmaceutical companies to develop pre-clinical assets and advance Super-ADC technology for therapeutic solutions. Partnerships aim to improve therapeutic index of existing assets and enable lower potency payloads in ADC field.
Scale indicators1 record
BioLoomics competitors and assessment
Company assessmentDirect peers
- Mersana Therapeutics: Clinical-stage ADC developer with proprietary conjugation and payload platforms (e.g., Dolasynthen, Immunosynthen). Directly comparable to BioLoomics as an ADC-platform company pursuing next-generation antibody conjugate technologies for oncology.
- CytomX Therapeutics: Developer of masked Probody therapeutics that are activated in the tumor microenvironment. Comparable to BioLoomics as a next-generation ADC/antibody platform company improving tumor selectivity and reducing off-target toxicity.
- ADC Therapeutics: Commercial-stage ADC company with marketed products (Zynlonta) and a pipeline of pyrrolobenzodiazepine-based ADCs. A direct comparable as an ADC-focused oncology company, although more clinically advanced than BioLoomics.
- Bolt Biotherapeutics: Developer of immune-stimulating ADCs (ISACs) combining tumor-targeting antibodies with immune agonists. Comparable to BioLoomics as a next-generation ADC platform pursuing novel mechanisms to overcome the limitations of traditional ADCs.
- Mythic Therapeutics: Developer of ADCs using a novel conjugation chemistry (FAT-Tag) designed to improve tumor selectivity. Closely comparable to BioLoomics as an early-to-mid-stage ADC-platform company working on differentiated payload-delivery approaches.
- Pyxis Oncology: ADC and immuno-oncology company building a pipeline of antibody-drug conjugates and immunotherapies. Comparable to BioLoomics as an ADC-focused oncology platform leveraging partnership and licensing strategies.
Emerging players
- Heidelberg Pharma: Developer of ADCs based on the amanitin payload (ATAC platform). Comparable as an emerging ADC-platform company differentiated by payload chemistry, with partnership deals similar to BioLoomics' intended model.
- Tubulis: European-based ADC platform company with proprietary conjugation and linker technologies. Comparable to BioLoomics as an early-stage ADC-platform peer focused on improving therapeutic index through novel chemistry.
Broad incumbents
- Daiichi Sankyo: Developer of Enhertu and Datroway in partnership with AstraZeneca. The dominant commercial-stage ADC player; comparable as the benchmark BioLoomics' Super-ADC must outperform on payload delivery and safety profile.
- Gilead Sciences (Kite/Immunomedics): Owner of Trodelvy via the Immunomedics acquisition and broader ADC strategy. A large incumbent pursuing ADC innovation in oncology; relevant comparable for understanding competitive dynamics facing BioLoomics.
Market position
Customer concentration
BioLoomics social profiles
Digital presenceBioLoomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioLoomics leadership team
Management profileNumber of profiles
Profiles3 records
BioLoomics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioLoomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioLoomics
What does BioLoomics do?
BioLoomics develops next-generation antibody-drug conjugates (Super-ADCs) using a proprietary directed evolution platform that engineers antibodies in human cells. The Super-ADCs incorporate oligomerizing membrane binding peptides that enhance tumor cell uptake and payload delivery, addressing the limitation of traditional ADCs that deliver less than 1% of chemotherapy payload to tumors. The company develops pre-clinical assets internally and intends to out-license or co-develop them with large pharmaceutical partners.
Is BioLoomics a public or private company?
BioLoomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioLoomics founded?
BioLoomics was founded in 2019. It employs 1 to 10 people.
Where is BioLoomics based?
BioLoomics is headquartered in Boulder, United States, in the North America region.
How does BioLoomics make money?
Two revenue lines are on record. Co-development Partnerships are the primary driver. The others are pre-clinical Asset Development.
Who are BioLoomics's main competitors?
Direct peers on record are Mersana Therapeutics, CytomX Therapeutics, ADC Therapeutics, Bolt Biotherapeutics, Mythic Therapeutics and Pyxis Oncology. Emerging players are Heidelberg Pharma and Tubulis. Broad incumbents are Daiichi Sankyo and Gilead Sciences (Kite/Immunomedics).
Does BioLoomics have an API?
No public API is recorded for BioLoomics.
What industry is BioLoomics in?
BioLoomics's product category is Biotechnology / Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.